Developing life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and patients to pharma and industry.
Greater patient involvement is among the stated aims of the ABPI, so why do companies up and down the country say the association’s Code of Conduct makes engagement difficult?
With the current mainstay of Parkinson’s treatment being more than 50 years old and doing nothing to slow or halt the progressive disease, the community is crying out for new drugs.
Over the last decade, treatments for the blood cancer myeloma have come on in leaps and bounds – but it remains incurable and unpredictable for individual patients and clinicians.<
To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unme
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl